Guard Therapeutics develops new drugs focusing on kidney disease. The company's pipeline consists of drug candidates based on the endogenous protein alpha-1-microglobulin.
Our goal is to create value for patients, society, and shareholders by developing kidney-protective drug treatments with high patient benefit, staying at the forefront of medical science, technology, and operational expertise.
